Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cervical Adenosquamous Cell Carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Cervical Adenosquamous Cell Carcinoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-003396-52 Sponsor Protocol Number: EORTC55994 Start Date*: 2009-09-24
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.
    Medical condition: Cervical carcinoma (including squamous cell carcinoma, adenosquamous cell or adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10008242 Cervical carcinoma stage IB LLT
    16.0 100000004864 10008244 Cervical carcinoma stage IIA LLT
    16.0 100000004864 10008245 Cervical carcinoma stage IIB LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003413-25 Sponsor Protocol Number: GCT1015-04 Start Date*: 2018-03-07
    Sponsor Name:Genmab A/S
    Full Title: A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer
    Medical condition: recurrent or metastatic cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000318-12 Sponsor Protocol Number: MITOCERV3 Start Date*: 2020-02-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer
    Medical condition: Locally advanced cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004844-20 Sponsor Protocol Number: ADXS001-02 Start Date*: 2017-05-08
    Sponsor Name:Advaxis, Inc
    Full Title: Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)
    Medical condition: High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10008231 Cervical cancer recurrent LLT
    19.1 100000004864 10008229 Cervical cancer LLT
    19.1 100000004864 10008236 Cervical cancer stage IV LLT
    19.1 100000004864 10008235 Cervical cancer stage III LLT
    19.1 100000004864 10008234 Cervical cancer stage II LLT
    19.1 100000004864 10008233 Cervical cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011542-25 Sponsor Protocol Number: C-2009-01 Start Date*: 2010-01-07
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: CIRCCa(Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent c...
    Medical condition: Metastatic/ Recurrent carinoma of cervix
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008224 Cervical adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000236-27 Sponsor Protocol Number: VEG105281 Start Date*: 2006-12-15
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Montherapy and Lapatinib Monotherapy in Subjects with FI...
    Medical condition: Patients with FIGO Stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) FR (Completed) EE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001440-53 Sponsor Protocol Number: MK3475-826 Start Date*: 2019-01-08
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or ...
    Medical condition: Cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004119-36 Sponsor Protocol Number: METOXY-LACC Start Date*: 2019-11-04
    Sponsor Name:Oslo University Hospital
    Full Title: Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer.
    Medical condition: Locally advanced cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004076-19 Sponsor Protocol Number: ENGOT-cx1/BGOG-cx1 Start Date*: 2013-10-28
    Sponsor Name:UZ Leuven / Belgian Gynaecological Oncology Group
    Full Title: ENGOT-cx1/BGOG-cx1: "Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg/m2 with or without concomitant and maintenance nintedanib (NINTEDANIB) in adv...
    Medical condition: Advanced or recurrent cervical carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001655-39 Sponsor Protocol Number: GCT1015-07 Start Date*: 2021-08-17
    Sponsor Name:Genmab A/S
    Full Title: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
    Medical condition: Second- or Third-Line Recurrent or Metastatic Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) DK (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003622-33 Sponsor Protocol Number: 2017/2608 Start Date*: 2018-04-03
    Sponsor Name:Gustave Roussy
    Full Title: Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer
    Medical condition: Locally Advanced Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008229 Cervical cancer LLT
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004657-77 Sponsor Protocol Number: BGB-A317-A1217-202 Start Date*: 2021-04-08
    Sponsor Name:BeiGene, Ltd.
    Full Title: Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previousl...
    Medical condition: Previously Treated Recurrent or Metastatic Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001804-12 Sponsor Protocol Number: ISA-HPV-01-12 Start Date*: 2016-12-01
    Sponsor Name:ISA Therapeutics B.V.
    Full Title: A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA1...
    Medical condition: Patients with advanced (Stage IIIb-IVa with involvement of lymph nodes beyond the renal vein) or metastatic (stage IVb) or recurrent HPV16 positive cervical cancer for whom no curative treatment op...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020977 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003583-40 Sponsor Protocol Number: MS200647_0017 Start Date*: 2020-07-07
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Contai...
    Medical condition: Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005491-28 Sponsor Protocol Number: MO29594 Start Date*: 2015-06-19
    Sponsor Name:Roche Farma, S.A en nombre de F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSIST...
    Medical condition: Metastatic, Recurrent or Persistent Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PT (Completed) PL (Completed) GR (Completed) FR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000120-33 Sponsor Protocol Number: C-550-01 Start Date*: 2018-11-19
    Sponsor Name:Agenus Inc.,
    Full Title: A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metas...
    Medical condition: Phase 1 – Part A dose escalation in patients with locally advanced, recurrent and/or metastatic solid tumor for which no standard therapy exists or standard therapy has failed. Phase 2 - Part B adv...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000350-19 Sponsor Protocol Number: R2810-ONC-1676 Start Date*: 2017-11-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma
    Medical condition: recurrent or metastatic, platinum-refractory cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001239-29 Sponsor Protocol Number: R2810-ONC-ISA-1981 Start Date*: 2021-07-22
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after First...
    Medical condition: Recurrent/Metastatic HPV16 Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003447-11 Sponsor Protocol Number: C-145-04 Start Date*: 2017-10-27
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
    Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001415-75 Sponsor Protocol Number: RC31/17/0213 Start Date*: 2019-11-15
    Sponsor Name:CHU de TOULOUSE
    Full Title: Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled ...
    Medical condition: Cervical cancer with positive para-aortic lymph nodes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 06:03:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA